Insider Transactions in Q2 2025 at Janux Therapeutics, Inc. (JANX)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 11
2025
|
Winston Kung |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+37.5%
|
-
|
|
Jun 11
2025
|
Jake Simson |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+37.5%
|
-
|
|
Jun 11
2025
|
Alana B. Mc Nulty |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+37.5%
|
-
|
|
Jun 11
2025
|
Natasha Hernday |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+30.05%
|
-
|
|
Jun 11
2025
|
Sheila Gujrathi |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+3.06%
|
-
|
|
Jun 11
2025
|
Eric Dobmeier |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+27.31%
|
-
|
|
Jun 11
2025
|
Vickie L Capps |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+4.82%
|
-
|
|
Jun 11
2025
|
Ronald W Barrett |
BUY
Grant, award, or other acquisition
|
Direct |
3,750
+37.5%
|
-
|
|
Jun 11
2025
|
Ra Capital Management, L.P. |
BUY
Grant, award, or other acquisition
|
Indirect |
3,750
+37.5%
|
-
|
|
Jun 02
2025
|
Janeen Noel Doyle Chief Corp. & Bus. Dev. Ofcr |
BUY
Grant, award, or other acquisition
|
Direct |
44,000
+50.0%
|
-
|
|
May 01
2025
|
Andrew Hollman Meyer Chief Business Officer |
SELL
Open market or private sale
|
Direct |
3,333
-1.96%
|
$106,656
$32.28 P/Share
|
|
May 01
2025
|
Andrew Hollman Meyer Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,333
+3.75%
|
$13,332
$4.21 P/Share
|
|
Apr 21
2025
|
Andrew Hollman Meyer Chief Business Officer |
SELL
Open market or private sale
|
Direct |
3,334
-3.9%
|
$100,020
$30.0 P/Share
|
|
Apr 21
2025
|
Andrew Hollman Meyer Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,334
+3.75%
|
$13,336
$4.21 P/Share
|